Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Strong stomach required by Elan shareholders

This article was originally published in Scrip

Executive Summary

Elan's shareholders are going to need a strong stomach if they are to swallow the Irish firm's latest proposal to generate value with its fresh pot of cash. Based on the most optimistic forecasts for sales of the basket of respiratory products in which it has just acquired a royalty interest, stockholders can look forward to an average annual return over the next four years of just 0.7% of the current share price of $11.61 in the form of a cash dividend linked to those royalties.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts